院内感染性肺炎(HAP)治療薬の世界市場

◆英語タイトル:Global Hospital-acquired Pneumonia (HAP) Drugs Market 2017-2021
◆商品コード:IRTNTR12755
◆発行会社(リサーチ会社):Technavio
◆発行日:2017年5月24日
◆ページ数:70
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、院内感染性肺炎(HAP)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、院内感染性肺炎(HAP)治療薬の世界市場規模及び予測、薬剤種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

・エグゼクティブサマリー
・院内感染性肺炎(HAP)治療薬の世界市場:市場概観
・院内感染性肺炎(HAP)治療薬の世界市場:業界の構造分析
・院内感染性肺炎(HAP)治療薬の世界市場:疾患概要
・院内感染性肺炎(HAP)治療薬の世界市場:市場規模及び予測
・院内感染性肺炎(HAP)治療薬の世界市場:薬剤種類別分析
・院内感染性肺炎(HAP)治療薬の世界市場:地域別分析
・院内感染性肺炎(HAP)治療薬の世界市場:アジア市場規模
・院内感染性肺炎(HAP)治療薬の世界市場:アメリカ市場規模
・院内感染性肺炎(HAP)治療薬の世界市場:ヨーロッパ市場規模
・院内感染性肺炎(HAP)治療薬の世界市場:成長要因
・院内感染性肺炎(HAP)治療薬の世界市場:課題
・院内感染性肺炎(HAP)治療薬の世界市場:製品パイプライン分析
・院内感染性肺炎(HAP)治療薬の世界市場:市場動向
・院内感染性肺炎(HAP)治療薬の世界市場:競争状況
・院内感染性肺炎(HAP)治療薬の世界市場:主要企業(ベンダー)分析
...

※上記の和訳は最新内容ではない場合があります。
【レポートの概要】

About Hospital Acquired Pneumonia (HAP) Drugs
HAP is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and mainly affects the microscopic air sacs called alveoli. This is primarily caused by infection by bacteria or viruses and sometimes with other microorganisms. It can be mainly distinguished on how the infection was acquired.

Technavio’s analysts forecast the global hospital acquired pneumonia drugs market to grow at a CAGR of 2.22% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global hospital acquired pneumonia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Hospital Acquired Pneumonia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• GlaxoSmithKline
• Merck
• Novartis
• Pfizer

[Other prominent vendors]
• Arsanis
• AstraZeneca
• Combioxin
• Mylan
• Shinogi
• Sun Pharmaceutical Industries
• Teva Pharmaceutical
• The Medicines Company
• Theravance Biopharma

[Market driver]
• Unmet demand due to lack of available treatment for MDR microorganisms
• For a full, detailed list, view our report

[Market challenge]
• Growing cases of MDR microorganisms
• For a full, detailed list, view our report

[Market trend]
• Combination therapy for the treatment of HAP
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Pneumonia
• Types of pneumonia

PART 06: Market landscape
• Market overview
• Market size and forecast

PART 07: Pipeline analysis

PART 08: Market segmentation by drug class
• Antibacterial drug
• Antiviral drugs
• Others

PART 09: Geographical segmentation
• HAP drugs market in Americas
• HAP drugs market in EMEA
• HAP drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Combination therapy for the treatment of HAP
• Growing preference for accurate diagnosis of disease
• Rising R&D for effective treatment against superbugs/MDR microorganisms

PART 13: Vendor landscape
• Competitive landscape

PART 14: Key vendor analysis
• GlaxoSmithKline
• Merck
• Novartis
• Pfizer
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits] Exhibit 01: Classification of pneumonia
Exhibit 02: Types of HAP
Exhibit 03: Symptoms and tests of HAP
Exhibit 04: Global HAP drugs market snapshot
Exhibit 05: Global HAP drugs market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis of HAP drugs market
Exhibit 07: Five forces analysis
Exhibit 08: Key pipeline molecules by vendors
Exhibit 09: Pipeline landscape
Exhibit 10: Segmentation of global HAP drugs market by drug class
Exhibit 11: Global HAP drugs market share by drug class 2016 and 2021
Exhibit 12: Uses and side effects of antibacterial drug
Exhibit 13: Global HAP antibacterial drugs market 2016-2021 ($ millions)
Exhibit 14: Causative microorganisms and empiric treatment
Exhibit 15: Brand mixtures for piperacillin-tazobactam
Exhibit 16: Global HAP antiviral drugs market 2016-2021 ($ millions)
Exhibit 17: Global HAP others drugs market 2016-2021 ($ millions)
Exhibit 18: Segmentation of global HAP drugs market based on geography 2016 and 2021
Exhibit 19: Global HAP drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 20: Market scenario in Americas
Exhibit 21: HAP drugs market in Americas 2016-2021 ($ millions)
Exhibit 22: Market scenario in EMEA
Exhibit 23: HAP drugs market in the EMEA 2016-2021 ($ millions)
Exhibit 24: Market scenario in APAC
Exhibit 25: HAP drugs market in the APAC 2016-2021 ($ millions)
Exhibit 26: Average percentage distribution of transplants by organ in US 1988-2016
Exhibit 27: Competitive structure analysis of global HAP drugs market 2016
Exhibit 28: GlaxoSmithKline: Key highlights
Exhibit 29: GlaxoSmithKline: Strength assessment
Exhibit 30: GlaxoSmithKline: Strategy assessment
Exhibit 31: GlaxoSmithKline: Opportunity assessment
Exhibit 32: Merck: Key highlights
Exhibit 33: Merck: Strength assessment
Exhibit 34: Merck: Strategy assessment
Exhibit 35: Merck: Opportunity assessment
Exhibit 36: Novartis: Key highlights
Exhibit 37: Novartis: Strength assessment
Exhibit 38: Novartis: Strategy assessment
Exhibit 39: Novartis: Opportunity assessment
Exhibit 40: Pfizer: Key highlights
Exhibit 41: Pfizer: Strength assessment
Exhibit 42: Pfizer: Strategy assessment
Exhibit 43: Pfizer: Opportunity assessment



【掲載企業】

GlaxoSmithKline, Merck, Novartis, Pfizer, Arsanis, AstraZeneca, Combioxin, Mylan, Shinogi, Sun Pharmaceutical Industries, Teva Pharmaceutical, The Medicines Company, and Theravance Biopharma.

【レポートのキーワード】

院内感染性肺炎、HAP治療薬

【リサーチ方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 院内感染性肺炎(HAP)治療薬の世界市場(Global Hospital-acquired Pneumonia (HAP) Drugs Market 2017-2021)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆